Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus announced significant milestones for its Evolus Rewards™ patient loyalty program, surpassing 1 million enrolled consumers and achieving 2 million Jeuveau® redemptions.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/29/2024 - 08:00 AM EDT

Achieves 2 Million Jeuveau^® Redemptions
Anticipates Launch of Club Evolus^™, the first consumer membership program by a neurotoxin manufacturer, on November 4, 2024

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpassed one million enrolled consumers and completed the two-millionth Jeuveau^® redemption in its Evolus Rewards^™ patient loyalty program.

“The achievement of these milestones underscores the success of our strategy to democratize beauty and make aesthetics accessible to a new generation of consumers,” said David Moatazedi, President and Chief Executive Officer. “Our easy-to-use, SMS-based loyalty program offers consumers an instant $40 savings on every Jeuveau^®treatment, while providing practices with the only co-branded solution to encourage repeat visits. We’re proud of the rapid adoption of this innovative program, which has grown to over 1 million consumers and achieved more than 2 million redemptions.

“We are excited to expand our loyalty offering with the upcoming launch of Club Evolus, the industry's first subscription-based consumer membership program from a neurotoxin manufacturer, debuting on November 4th. Powered by the same proprietary digital platform that enhances the practice experience, Club Evolus will offer consumers even more value and convenience.”

Evolus Rewards^™ was launched in 2020 soon after Jeuveau^® was approved by the FDA in 2019. The program offers enrolled patients $40 off Jeuveau^® treatments every 90 days at participating providers. The program enhances convenience and ease by delivering a fun, frictionless experience with instant rewards. This approach allows both patients and practices to effortlessly engage with the program.

Evolus Rewards^™ supports the company’s mission of partnering with its customers and driving consumers back to their practices with co-branded reminders and text messages, while attracting the next generation of beauty consumers considering aesthetic injectables. On average, practices participating in Evolus Rewards™ experience significantly higher revenue growth than non-participating practices.

Importantly, more than half of new entrants to Evolus Rewards^™ are millennials or younger. This demographic represents the future of the aesthetics industry and is a highly sought-after audience for providers looking to expand their businesses.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse^™, and the exclusive distributor in Europe of Estyme^®, a line of unique injectable hyaluronic acid (HA) gels. These injectable HA gels are currently in the late stages of the regulatory approval process, with plans, upon approval, for a launch starting in 2025. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau^® and Nuceiva^®, are registered trademarks and Evolysse^™ is a trademark of Evolus, Inc.
Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme^® is a trademark of Symatese Aesthetics S.A.S.